These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 20675713)
1. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Chan YM; Keramaris-Vrantsis E; Lidov HG; Norton JH; Zinchenko N; Gruber HE; Thresher R; Blake DJ; Ashar J; Rosenfeld J; Lu QL Hum Mol Genet; 2010 Oct; 19(20):3995-4006. PubMed ID: 20675713 [TBL] [Abstract][Full Text] [Related]
2. Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes. Blaeser A; Keramaris E; Chan YM; Sparks S; Cowley D; Xiao X; Lu QL Hum Genet; 2013 Aug; 132(8):923-34. PubMed ID: 23591631 [TBL] [Abstract][Full Text] [Related]
3. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I. Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318 [TBL] [Abstract][Full Text] [Related]
4. Prenatal muscle development in a mouse model for the secondary dystroglycanopathies. Kim J; Hopkinson M; Kavishwar M; Fernandez-Fuente M; Brown SC Skelet Muscle; 2016; 6():3. PubMed ID: 26900448 [TBL] [Abstract][Full Text] [Related]
5. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions. Xu L; Lu PJ; Wang CH; Keramaris E; Qiao C; Xiao B; Blake DJ; Xiao X; Lu QL Mol Ther; 2013 Oct; 21(10):1832-40. PubMed ID: 23817215 [TBL] [Abstract][Full Text] [Related]
6. Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies. Ackroyd MR; Skordis L; Kaluarachchi M; Godwin J; Prior S; Fidanboylu M; Piercy RJ; Muntoni F; Brown SC Brain; 2009 Feb; 132(Pt 2):439-51. PubMed ID: 19155270 [TBL] [Abstract][Full Text] [Related]
7. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression. Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834 [TBL] [Abstract][Full Text] [Related]
8. Restoration of Functional Glycosylation of α-Dystroglycan in FKRP Mutant Mice Is Associated with Muscle Regeneration. Awano H; Blaeser A; Keramaris E; Xu L; Tucker J; Wu B; Lu P; Lu QL Am J Pathol; 2015 Jul; 185(7):2025-37. PubMed ID: 25976249 [TBL] [Abstract][Full Text] [Related]
10. Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). Thornhill P; Bassett D; Lochmüller H; Bushby K; Straub V Brain; 2008 Jun; 131(Pt 6):1551-61. PubMed ID: 18477595 [TBL] [Abstract][Full Text] [Related]
11. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery. Qiao C; Wang CH; Zhao C; Lu P; Awano H; Xiao B; Li J; Yuan Z; Dai Y; Martin CB; Li J; Lu Q; Xiao X Mol Ther; 2014 Nov; 22(11):1890-9. PubMed ID: 25048216 [TBL] [Abstract][Full Text] [Related]
12. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression. Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821 [TBL] [Abstract][Full Text] [Related]
13. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726 [TBL] [Abstract][Full Text] [Related]
14. The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Whitmore C; Fernandez-Fuente M; Booler H; Parr C; Kavishwar M; Ashraf A; Lacey E; Kim J; Terry R; Ackroyd MR; Wells KE; Muntoni F; Wells DJ; Brown SC Hum Mol Genet; 2014 Apr; 23(7):1842-55. PubMed ID: 24234655 [TBL] [Abstract][Full Text] [Related]
15. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice. Cataldi MP; Lu P; Blaeser A; Lu QL Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693 [TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein. Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668 [TBL] [Abstract][Full Text] [Related]
17. NAD+ enhances ribitol and ribose rescue of α-dystroglycan functional glycosylation in human FKRP-mutant myotubes. Ortiz-Cordero C; Magli A; Dhoke NR; Kuebler T; Selvaraj S; Oliveira NA; Zhou H; Sham YY; Bang AG; Perlingeiro RC Elife; 2021 Jan; 10():. PubMed ID: 33513091 [TBL] [Abstract][Full Text] [Related]
18. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Godfrey C; Clement E; Mein R; Brockington M; Smith J; Talim B; Straub V; Robb S; Quinlivan R; Feng L; Jimenez-Mallebrera C; Mercuri E; Manzur AY; Kinali M; Torelli S; Brown SC; Sewry CA; Bushby K; Topaloglu H; North K; Abbs S; Muntoni F Brain; 2007 Oct; 130(Pt 10):2725-35. PubMed ID: 17878207 [TBL] [Abstract][Full Text] [Related]
19. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation. Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227 [TBL] [Abstract][Full Text] [Related]
20. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy. Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM Skelet Muscle; 2016; 6():20. PubMed ID: 27257474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]